Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H32N2O2 |
Molecular Weight | 356.5017 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N3CCCC3)C(=O)CC4=CC=CC=C4
InChI
InChIKey=PGZRDDYTKFZSFR-ONTIZHBOSA-N
InChI=1S/C22H32N2O2/c1-23(21(25)16-18-8-3-2-4-9-18)19-10-12-22(11-7-15-26-22)17-20(19)24-13-5-6-14-24/h2-4,8-9,19-20H,5-7,10-17H2,1H3/t19-,20-,22-/m0/s1
Molecular Formula | C22H32N2O2 |
Molecular Weight | 356.5017 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P41145 Gene ID: 4986.0 Gene Symbol: OPRK1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/8632704 |
3.8 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
[3H]U-69593 a highly selective ligand for the opioid kappa receptor. | 1985 Feb 26 |
|
kappa-Opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. | 1995 Jul 18 |
|
Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. | 1995 Sep |
|
Prevention by morphine of apomorphine- and oxytocin-induced penile erection and yawning: involvement of nitric oxide. | 1997 May |
|
Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. | 1998 Mar |
|
Sensitization of the adenylyl cyclase system in cloned kappa-opioid receptor-transfected cells following sustained agonist treatment: A chimeric study using G protein alpha(i)2/alpha(q) subunits. | 1999 Dec |
|
U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking. | 1999 Jun |
|
G-protein-coupled receptor heterodimerization modulates receptor function. | 1999 Jun 17 |
|
Kappa-opioid receptor activation prevents alterations in mesocortical dopamine neurotransmission that occur during abstinence from cocaine. | 2000 |
|
Reinstatement of extinguished drug-taking behavior in rats: effect of the kappa-opioid receptor agonist, U69593. | 2000 Jul |
|
Effects of the kappa-opioid receptor agonist, U69593, on the development of sensitization and on the maintenance of cocaine self-administration. | 2001 Apr |
|
Oligomerization of opioid receptors with beta 2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation. | 2001 Jan 2 |
|
Kappa opioid receptor stimulation decreases amphetamine-induced behavior and neuropeptide mRNA expression in the striatum. | 2001 Sep 10 |
|
Kappa opioids inhibit physiologically identified medullary pain modulating neurons and reduce morphine antinociception. | 2005 Mar |
|
Mu- and kappa-opioids induce the differentiation of embryonic stem cells to neural progenitors. | 2006 Nov 3 |
|
Sex differences in the potency of kappa opioids and mixed-action opioids administered systemically and at the site of inflammation against capsaicin-induced hyperalgesia in rats. | 2007 Apr |
|
Pharmacological and genetic manipulation of kappa opioid receptors: effects on cocaine- and pentylenetetrazol-induced convulsions and seizure kindling. | 2007 Mar |
|
Effect of kappa-opioid receptor agonists U69593, U50488H, spiradoline and salvinorin A on cocaine-induced drug-seeking in rats. | 2009 Dec |
|
Discovery of aminobenzyloxyarylamides as κ opioid receptor selective antagonists: application to preclinical development of a κ opioid receptor antagonist receptor occupancy tracer. | 2011 Dec 8 |
|
Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine. | 2011 Oct 13 |
|
Essential structure of opioid κ receptor agonist nalfurafine for binding to the κ receptor 2: synthesis of decahydro(iminoethano)phenanthrene derivatives and their pharmacologies. | 2012 Aug 1 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2826959
in rats: in the intestinal transit test U-69,593 at doses between 0.5 and 15 mg/kg i.p. only slightly slowed intestinal transit of a charcoal meal in rats with no dose-relation; it partly but significantly antagonized morphine-induced constipation
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8632704
Receptor binding studies were performed to characterize the properties of subtypes of kappa opioid receptors in membrane preparations of human cerebral cortex. [3H]U69,593 ([3H]U69), a selective kappa 1-agonist, and [3H]diprenorphine ([3H]DIP), a non-selective opioid antagonist, in the presence of 1 microM each of DAMGO, DPDPE and U-69 to block mu-, delta-, and kappa 1-sites, labeled single population of binding sites, respectively. [3H]U-69 binding sites (KD = 3.8 +/- 0.2 nM, Bmax = 6.3 +/- 0.2 fmol/mg protein) had a binding profile that correspond to kappa 1-receptor.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 19:37:48 GMT 2023
by
admin
on
Fri Dec 15 19:37:48 GMT 2023
|
Record UNII |
J5S4K6TKTG
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
J5S4K6TKTG
Created by
admin on Fri Dec 15 19:37:48 GMT 2023 , Edited by admin on Fri Dec 15 19:37:48 GMT 2023
|
PRIMARY | |||
|
96744-75-1
Created by
admin on Fri Dec 15 19:37:48 GMT 2023 , Edited by admin on Fri Dec 15 19:37:48 GMT 2023
|
PRIMARY | |||
|
73357
Created by
admin on Fri Dec 15 19:37:48 GMT 2023 , Edited by admin on Fri Dec 15 19:37:48 GMT 2023
|
PRIMARY | |||
|
U 69593
Created by
admin on Fri Dec 15 19:37:49 GMT 2023 , Edited by admin on Fri Dec 15 19:37:49 GMT 2023
|
PRIMARY | |||
|
DTXSID3046326
Created by
admin on Fri Dec 15 19:37:48 GMT 2023 , Edited by admin on Fri Dec 15 19:37:48 GMT 2023
|
PRIMARY | |||
|
105104
Created by
admin on Fri Dec 15 19:37:49 GMT 2023 , Edited by admin on Fri Dec 15 19:37:49 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
LABELED -> NON-LABELED |
|
||
|
TARGET -> AGONIST |
[35S]-GTPγS Assay Emax
EC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|